Form 4: Cabaletta Bio's General Counsel, Michael Gerard, Reports Stock Option Grant

Michael Gerard, General Counsel of Cabaletta Bio, Inc., reports the acquisition of stock options for 100,000 shares on March 1, 2024.

Summary

• Michael Gerard, the General Counsel of Cabaletta Bio, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 1, 2024.
• Gerard acquired stock options for 100,000 shares of Cabaletta Bio's common stock at an exercise price of $23.97.
• These options vest over time, starting with 25% on March 1, 2025, and the remainder in equal quarterly installments over the following three years, contingent upon continued service.
• Following the reported transaction, Gerard directly owns derivative securities for 100,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The vesting schedule suggests a positive outlook for the company's future.

Positives

• The grant of stock options to the General Counsel aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests an expectation of continued service from the General Counsel.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotech companies.
• The size of the grant and the vesting schedule are typical for a General Counsel position in a company of Cabaletta Bio's size and stage of development.
• Comparable companies like Arcellx, Inc. and Cartesian Therapeutics, Inc. also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates